For a cannabis-medicine practice, this is not a headline to shrug off
The PCAC meeting, including testimony from key opinion leaders, physicians, and pharmacists, did not create these expectations
The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and obesity: Semaglutide, sold as Ozempic, Wegovy Tirzepatide, sold as Mounjaro Dulaglutide, sold as Trulicity Liraglutide, sold as Saxenda The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)
An earlier short-term randomized trial did not find significant changes in several oxidative-stress measures
Lightweight, non-greasy cosmetic serum